News for Orthocell Limited (OCC.AX)

Telix Pharmaceuticals (ASX:TLX) has joined a somewhat quiet cohort of ASX biotech companies having a pretty good run lately.

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer…

This was a seven-week closing high, achieved amidst positive sentiment as investors react to Donald Trump’s “Stargate” plan for AI investment.

Inflation edged up more than expected, from 2.1% to 2.3%. More importantly, trimmed mean inflation came in at 3.2%.

Jobs data today surprised analysts, with unemployment falling to 3.9%. Now the odds of an early interest rate cut have lengthened.

On Chris Judd’s Talk Ya Book today, the AFL legend sat down with Orthocell…

The stock’s bull run over the last two months has seen its share price more than double as investors eye the lucrative $1.6B nerve repair market in the US.

Orthocell (ASX:OCC) has announced its receipt of commitments for $17M in funding via placement to bankroll the US launch of Remplir.

The local bourse shed some of the gains from recent weeks as investors took profits and re-evaluated their portfolios.

The major U.S. index futures are currently pointing to a higher open on Tuesday, with stocks likely to move back to the upside following the weakness seen in the previous session.

The ASX200 closed down 0.35% at 8,176 points. Iron ore prices fell from US$114/tn to US$108/tn in Singapore on news the Chinese government’s stimulus will focus more on boosting domestic spending.

The bank stocks rallied leading the index higher, but Energy and mining stocks slumped in the wake of falling commodity prices.

Bank stocks have surged and dragged the market higher with the big 4 all outperforming and dragging the bourse higher.

Losses force BHP’s nickel shutdownBHP will suspend nickel mining after huge losses in a move that casts doubt over thousands of jobs in Western Australia and will inflame tensions with the Albanese go

The ASX200 had a strong day closing up 0.93%. All sectors closed in the green with top performer Real Estate jumping 1.5%,  followed closely by IT and Healthcare.

The ASX200 closed around a quarter of a per cent up with…

Biotech tends to follow a four to five year market cycle and…

The US dental membrane and bone graft substitute market is growing at a CAGR of 11.4% from 2023 to 2028....

Increasing investments in stem cell banking, cell manufacturing, and bioprocessing facilities are pivotal in advancing the commercialization and...